Table 2.

MR^4.5 response rates (percentage) by or at 3-, 5- and 10-years. Only studies with ≥3 years follow-up. All rates are ‘by’ except for those reported for Guilhot et al. [27].

Ref.	Study	Initial TKI	N	Median age (y)	3-y MR4.5 rate	5-y MR4.5 rate	10-y MR4.5 rate
De Lavallade et al. [88]	Hammersmith	IM 400	204	46	4f	8f	NR
Branford et al. [22]	Adelaide	IM 400/600/800	423	NR	NR	NR	52a
Cortes et al. [25]	DASISION	IM 400	260	49	13	33	NA
Hochhaus et al. [24], Kantarjian et al. [26]	ENESTnd	IM 400	283	46	15	31	39
Zhang et al. [69]	Peking	IM 400	1373	41	NR	NR	43b
Guilhot et al. [27]	French SPIRIT	IM 400	223	50	24	23	27
Hehlmann et al. [30, 31]	German Study IV	IM 400	401	53	35	49	67
Guilhot et al. [27]	French SPIRIT	IM 400 + LDAC	172	51	22	22	34
Hehlmann et al. [30, 31]	German Study IV	IM 400 + LDAC	158	51	31	50	70
Guilhot et al. [27]	French SPIRIT	IM 400 + IFNα	221	55	26	33	29
Hehlmann et al. [30, 31]	German Study IV	IM 400 + IFNα	430	53	38	54	74
Guilhot et al. [27]	French SPIRIT	IM 600	171	51	24	31	36
Hehlmann et al. [30, 31]	German Study IV	IM 800	399	52	43	58	71
Etienne et al. [43]	French	IM 400, DAS 100,NIL 600	398	62	31e	40e	52e
Geelen et al. [90]	Dutch	IM 400, DAS 100, NIL 600	434	58	30c	56d	57
Cortes et al. [25]	DASISION	DAS 100	259	46	20	42	NA
Matsumura et al. [28]	JALSG	DAS 100	227	53	45	NA	NA
Matsumura et al. [28]	JALSG	NIL 600	227	53	41	NA	NA
Hochhaus et al. [24], Kantarjian et al. [26]	ENESTnd	NIL 600	282	47	32	54	61
Hochhaus et al. [24], Kantarjian et al. [26]	ENESTnd	NIL 800	281	47	28	52	61
Masarova et al. [93]	MDACC	NIL 800	122	51	61	72	75

TKI doses are in mg/d. Percentages are rounded.

MR^4.5 BCR::ABL1 ≤ 0.0032%^IS, other abbreviations as in Table 1.

^a8-y, ^b7-y, ^c2-y, ^d4-y, ^esustained (at least 24 months), ^frates of ‘complete molecular response (CMR)’ defined as two consecutive samples with no detectable transcripts.